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Abstract: 
Background: Little research has been conducted regarding the relationship 
between sleep disorders and different pain types in Parkinson’s disease 
(PD).  
Objective: To explore the influence of the various pain subtypes 
experienced by PD patients on sleep.  
Methods: Three-hundred consecutive PD patients were assessed with the 
PD Sleep Scale-Version 2 (PDSS-2), King’s PD Pain Scale (KPPS), King’s PD 
Pain Questionnaire (KPPQ), Visual Analog Scales for Pain (VAS-Pain), and 
Hospital Anxiety and Depression Scale.  
Results: According to the PDSS-2, 99.3% of our sample suffered from at 
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least one sleep issue. Those who reported experiencing any modality of 
pain suffered significantly more from sleep disorders than those who did 
not (all, p<0.003). The PDSS-2 showed moderate-to-high correlations with 
the KPPS (rS=0.57), KPPQ (0.57), and VAS-Pain (0.35). When PDSS-2 
items 10-12 (pain-related) were excluded, the correlation values decreased 
to 0.50, 0.51, and 0.28, respectively, while these items showed moderate-
to-high correlations with KPPS (0.56), KPPQ (0.54), and VAS-Pain (0.42). 
Among the variables analyzed, multiple linear regression models suggested 
that KPPS and KPPQ were the most relevant predictors of sleep disorders 
(as per the PDSS-2), although following exclusion of PDSS-2 pain items 
depression was the relevant predictor. Depression and anxiety were the 
most relevant predictors in the analysis involving the VAS-Pain. Regression 
analysis considering only the KPPS domains showed that nocturnal and 
musculoskeletal pain were the best predictors of overall nocturnal sleep 
disorder.  
Conclusions: Pain showed a moderate association with nocturnal sleep 
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Background: Little research has been conducted regarding the relationship between sleep 
disorders and different pain types in Parkinson’s disease (PD). 
Objective: To explore the influence of the various pain subtypes experienced by PD patients on 
sleep. 
Methods: Three-hundred consecutive PD patients were assessed with the PD Sleep Scale-
Version 2 (PDSS-2), King’s PD Pain Scale (KPPS), King’s PD Pain Questionnaire (KPPQ), 
Visual Analog Scales for Pain (VAS-Pain), and Hospital Anxiety and Depression Scale. 
Results: According to the PDSS-2, 99.3% of our sample suffered from at least one sleep issue. 
Those who reported experiencing any modality of pain suffered significantly more from sleep 
disorders than those who did not (all, p<0.003). The PDSS-2 showed moderate-to-high 
correlations with the KPPS (rS=0.57), KPPQ (0.57), and VAS-Pain (0.35). When PDSS-2 items 
10-12 (pain-related) were excluded, the correlation values decreased to 0.50., 0.51, and 0.28, 
respectively, while these items showed moderate-to-high correlations with KPPS (0.56), KPPQ 
(0.54), and VAS-Pain (0.42). Among the variables analyzed, multiple linear regression models 
suggested that KPPS and KPPQ were the most relevant predictors of sleep disorders (as per 
the PDSS-2), although following exclusion of PDSS-2 pain items depression was the relevant 
predictor. Depression and anxiety were the most relevant predictors in the analysis involving the 
VAS-Pain. Regression analysis considering only the KPPS domains showed that nocturnal and 
musculoskeletal pain were the best predictors of overall nocturnal sleep disorder. 
Conclusions: Pain showed a moderate association with nocturnal sleep dysfunction in PD. 
Some pain subtypes had a greater effect on sleep than others. 
 






A range of sleep disorders and subtypes of pain, are very prevalent non-motor symptoms of 3 
Parkinson’s disease (PD) that occur from the prodromal to the palliative stages of PD (1-5). 4 
Sleep dysfunction, which affects 60-98% of PD patients, may be manifested as insomnia, sleep 5 
disruption, sudden onset of sleep, rapid-eye-movement (REM) sleep behavior disorder, non-6 
REM parasomnias, and restless legs syndrome (6-8). Surveys suggest that insomnia affects 7 
46% of PD patients, vivid dreams 34%, acting out while dreaming 36%, and restless legs 8 
syndrome 42% (1). Depression, anxiety, cognitive problems, stress, and daytime sleepiness 9 
have been found to result from these conditions, and sleep disorders in PD have a negative 10 
impact on patients’ quality of life (QoL) (9,10).  11 
On the other hand, using the King’s Parkinson’s Disease Pain Scale (KPPS) (11), the syndromic 12 
nature of pain has been formally subdivided into several patterns. Prior research has shown that 13 
the prevalence of pain is 68-81% in PD patients (12-14) and that it can be manifested in several 14 
modalities, such as musculoskeletal (41-89%), dystonic (15-17%), radicular-neuropathic (27-15 
32%), and central pain (4-22%) (2,12,14-18). Furthermore, 35% of PD patients are affected by 16 
two types of pain, 10% by three, and 2% by four (14). Pain can become crippling in a subset of 17 
PD patients, affect their ability to conduct activities of daily living (ADL) (13,19), and negatively 18 
impact their QoL (20-22). Yet, despite the impact of this non-motor symptom, pain often remains 19 
underdiagnosed and undeclared (23).  20 
PD patients with pain have been found to experience poorer sleep quality and more sleep 21 
disorders than patients without pain (24). Using the Parkinson’s Disease Sleep Scale-Version 2 22 
(PDSS-2) (25) and the KPPS (11), the present study seeks both to explore the influence of the 23 
various modalities of pain experienced by PD patients on sleep disorders and to examine the 24 




relationship between sleep disorders and other factors, such as anxiety and depression, motor 25 




International, multicenter, observational, cross-sectional study. 30 
Patients 31 
Consecutive PD patients were included in this study if they were diagnosed with PD according 32 
to the UK PD Brain Bank criteria (26) and if they declared unexplained pains on item 10 of the 33 
Non-Motor Symptoms Questionnaire (27). However, if patients had an alternative or uncertain 34 
diagnosis of PD or drug-induced PD, were unable to consent, had dementia as diagnosed by 35 
international criteria, or were diagnosed with known conditions that cause pain unrelated to PD 36 
(e.g. arthritis, malignancy, etc.), they were excluded from this study (28). 37 
Patients were recruited from nine different movement disorder centers across the United 38 
Kingdom (eight) and Romania (one) from August 2013 to February 2016. This study was 39 
conducted under the UK’s National Institute of Health Research’s portfolio of studies (UKCRN 40 
No. 13344) (28). 41 
Ethical issues 42 
The study was approved by the respective hospital ethical committees/institutional review 43 
boards. All participants provided informed consent before inclusion in the study. 44 
Assessments 45 




Socio-demographic data and disease history (i.e. sex, age, ethnicity, PD duration, current 46 
treatment, and surgery) were collected from all patients. According to Tomlinson et al., levodopa 47 
equivalent daily dose (LEDD) was also calculated (29). 48 
The following instruments were used to assess each patient: 49 
1. Parkinson’s Disease Sleep Scale-Version 2 (PDSS-2) (25), a 15-item, patient-completed 50 
clinical tool used to assess the frequency of sleep disturbances during the past week in PD 51 
patients. Items 10, 11, and 12 of the PDSS-2 directly assess pain while sleeping or when 52 
waking up. 53 
2. Hoehn-Yahr classification (HY) (30), a five-stage system that classifies PD on a 54 
continuum from unilateral expression of the disease to the most severe. 55 
3. Scales for Outcomes in Parkinson’s Disease-Motor (SCOPA-Motor) (31), a 21-item 56 
scale that measures motor impairment, difficulty with ADL, and motor complications. 57 
4. Non-Motor Symptoms Scale (NMSS) (32), a 30-item scale that considers the frequency 58 
and severity of the non-motor symptoms of PD grouped into nine domains: cardiovascular, 59 
sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, 60 
gastrointestinal tract, urinary function, sexual function, and miscellaneous. Item 27 of the NMSS 61 
directly inquires about unexplained pains. 62 
5. Clinical Impression of Severity Index for PD (CISI-PD) (33), an overall estimate of PD 63 
based on motor signs, disability, motor complications, and cognitive status. 64 
6. King’s Parkinson’s Pain Scale (KPPS) (11), a 14-item scale that evaluates the types of 65 
pain suffered by PD patients: musculoskeletal, chronic, fluctuation-related, nocturnal, oro-facial, 66 
discoloration and oedema/swelling, and radicular pain. Each item is rated by the clinician 67 
according to its severity (from 0 to 3) and frequency (from 0 to 4). An item’s score is then 68 




calculated as the product of each pain type’s frequency and severity, and a total score is 69 
calculated by summing the scores of each item. KPPS time frame is “the past month”. 70 
7.   King’s Parkinson’s Pain Questionnaire (KPPQ) (28), a patient-completed derivative of 71 
the KPPS, asks about the same pain modalities as the KPPS, and only provides information 72 
regarding the presence or absence of 14 specific types of pain in a given patient. The time 73 
framework is “past month”.   74 
8. Visual Analog Scales for Pain Severity and Frequency (VAS-Pain) (34). A VAS-Pain 75 
total score was calculated by multiplying both scales, whose time framework was “past month”.  76 
9 Hospital Anxiety and Depression Scale (HADS) (35), which is a 14-item, patient-77 
completed scale with subscales for anxiety and depression. 78 
10. EQ-5D-3L (36), which contains five items that inquire about mobility, self-care, usual 79 
activities, pain/discomfort, and anxiety/depression, as well as a visual analog scale that 80 
assesses current health status. 81 
11. Parkinson’s Disease Questionnaire-8 items (PDQ-8) (37), a PD-specific health-related 82 
QoL measure. Item 8 of the PDQ-8 specifically asks about painful muscle cramps or spasms. 83 
 84 
Data Analysis 85 
Data were anonymized and sent to the National Center of Epidemiology, Carlos III Institute of 86 
Health, in Madrid, Spain for analysis. 87 
Socio-demographic, historical data, and rating scales scores were examined using descriptive 88 
statistics (i.e. mean, median, and, standard deviation). Main data showed non-normal 89 
distribution (Shapiro-Francia test); therefore non-parametric statistical tests were used. 90 




The prevalence of each sleep symptom assessed by the PDSS-2 was calculated by considering 91 
an item score ≥1 to be the presence of that symptom and an item score of 0 to be its absence. 92 
Furthermore, patients were divided into groups using the prevalence of each of the seven pain 93 
modalities (domains) assessed by the KPPS, which were calculated using the same method 94 
described above (15). Then, after excluding the PDSS-2 pain-related items (items 10-12: 95 
“PDSS-2 Pain”), the effect of each type of pain on non-pain-related PDSS-2 score was 96 
determined by comparing the means of the two groups (with and without that specific pain) and 97 
by applying the Mann-Whitney test.  98 
The association of the PDSS-2 with the KPPS and other clinical variables evaluating pain 99 
present in the study was assessed by Spearman correlations. Partial correlations were also 100 
used to adjust these associations for age, PD duration, SCOPA motor examination, and LEDD. 101 
Coefficient values higher than 0.50 were deemed strong correlations and those from 0.30 to 102 
0.49 moderate ones.  103 
The influence of pain on PDSS-2 score was determined using multiple linear regression models 104 
in which the dependent variable was the PDSS-2 and the independent ones were (after 105 
checking for association, collinearity, and interaction): SCOPA-Motor ADL and complications 106 
sections, HADS-Anxiety, HADS-Depression, and the NMSS gastrointestinal and urinary 107 
domains. Each model also included one of the following pain measures as an independent 108 
variable: KPPS, KPPQ, and VAS-Pain. In order to explore the influence of each type of pain on 109 
nocturnal sleep issues, another multiple linear regression analysis was conducted using the 110 
KPPS domains as predictors of PDSS-2 total score.  111 
To exclude the influence of the PDSS-2 pain-related items on the findings, the correlation 112 
coefficients and multiple regression models were recalculated after excluding the “PDSS-2 Pain” 113 
dimension. 114 




For further analysis regarding the PDSS-2 total score, Kruskal-Wallis and Mann-Whitney tests 115 
were conducted to determine if there were significant differences between sexes, groups of age, 116 
PD duration, and LEDD (based on quartiles) in reference to the scale. Finally, Spearman rank 117 
correlations were calculated between PDSS-2 and the remaining assessments in the study.  118 
 119 
Results 120 
Three hundred PD patients, most of them males (59.7%) and predominantly Caucasians 121 
(84.8%) were included in the study. Median HY was 2 with an interquartile range of 2–3 (limits: 122 
1–5). One hundred and fifty one patients (50.3%) had Postural instability and gait difficulty PD 123 
subtype; 93 (31.0%) showed tremor predominant subtype; and 56 (18.7%) were indeterminate 124 
(38,39). Other descriptive data of the sample are displayed in the Table 1. On the PDSS-2, the 125 
average total score was 18.57±10.89 (range: 0–51), while scores were 22.85±19.45 (0–102) on 126 
the KPPS, 3.96±2.56 (1–12) on the KPPQ, and 32.78±24.40 (0–100) on the VAS-Pain.  127 
Table 2 shows the prevalence rates for each sleep issue assessed by the PDSS-2; 99.3% of 128 
our sample was afflicted by at least one sleep problem. Moreover, as shown in Table 3, those 129 
who reported experiencing any modality of pain suffered from significantly more severe non-130 
pain-related sleep disorders than those who did not (all, p<0.003).  131 
The PDSS-2 was moderately or highly correlated with the KPPS domains of fluctuation-related 132 
pain (rS=0.34), nocturnal pain (0.52), discoloration and oedema/swelling related pain (0.31), and 133 
radicular pain (0.32) as well as with the KPPS total score (0.57), whereas it showed weak 134 
relationships with the remaining KPPS domains (rS=0.20–0.28). Similarly, the correlations with 135 
KPPQ (0.57) and VAS-Pain (0.35) were moderate-to-high. These coefficients were only slightly 136 
modified in the partial correlation analysis of total scores (KPPS, 0.51; KPPQ, 0.52; and VAS-137 
Pain, 0.31). When the “PDSS-2 Pain” component was excluded from the PDSS-2 total score, all 138 




correlation coefficients with total scores decreased 0.06-0.07 (KPPS, 0.50; KPPQ, 0.51, VAS-139 
Pain, 0.28), and 0.04 in average (0.01-0.08) with KPPS domains. Furthermore, the two QoL 140 
assessments showed moderate-to-high associations with the three pain measures in the study: 141 
-0.45 to -0.60 for the EQ-5D-3L and 0.42 to 0.59 for the PDQ-8. 142 
Using “PDSS-2 Pain” (the sum of items 10-12), the following correlations were found between 143 
this pain score and other measures in the study: the KPPS domains of musculoskeletal 144 
(rS=0.30), fluctuation-related (0.32), nocturnal (0.52), and radicular (0.37) pain as well as its total 145 
score (0.56); the KPPQ (0.54); VAS-Pain (0.42); the EQ-5D-3L’s pain/discomfort question 146 
(0.37); and PDQ-8 item 8 (0.43).  147 
Table 4 shows the results of six multiple linear regression models. In the analyses using the 148 
KPPS and KPPQ, pain was shown to be the most powerful predictor of the sleep disorders 149 
assessed by the PDSS-2 (p<0.001); however, in the analysis using the VAS-Pain, depression 150 
and then anxiety were the best predictors of these sleep problems (p<0.001). However, when 151 
the “PDSS-2 Pain” domain was excluded, depression and urinary disorders were first and 152 
second determinants in importance in the models with KPPS and KPPQ, whereas there were no 153 
changes in those of the VAS-Pain model (Table 4). 154 
An additional multiple linear regression model using the KPPS pain modalities as predictors of 155 
the PDSS-2 was explored. In this model, only nocturnal (p<0.001; beta=0.38) and 156 
musculoskeletal (p=0.003; beta=0.15) pain were significant determinants of overall nocturnal 157 
sleep disorder, a finding that was not modified by excluding the pain-related items of the PDSS-158 
2 (Table 5).  159 
Patients who had longer PD duration (p=0.001) and higher LEDD (p<0.001) also reported 160 
significantly more severe sleep disturbances. Moreover, the PDSS-2 showed moderate-to-high 161 
correlations with the other clinical measures in the study: CISI total score (rS=0.39); HADS-162 




Anxiety (0.50); HADS-Depression (0.54); EQ-5D summary index (-0.49); PDQ-8 summary index 163 
(0.60); SCOPA-Motor ADL (0.43), complications (0.38), and total score (0.40); the NMSS 164 
domains of sleep/fatigue (0.58), mood/apathy (0.34), gastrointestinal (0.37), urinary (0.35), and 165 
its total score (0.54).  166 
 167 
Discussion 168 
In line with previous findings, almost all patients in our sample (99.3%) declared having at least 169 
one nocturnal sleep dysfunction according to the PDSS-2, confirming the high prevalence of this 170 
non-motor symptom in PD (6). The most prevalent of these issues in our study were nocturia 171 
(85.0%), tiredness and sleepiness upon waking (72.0%), and poor sleep quality (71.7%). While 172 
some studies have found figures that are similar to ours, other studies did not (40-42); however, 173 
the PDSS-2 has never been used to analyze the prevalence of nocturnal sleep disorders in PD, 174 
and, therefore, our results cannot be compared at present with other studies. For example, 175 
problems related to “PDSS-2 Pain” showed prevalence rates of 44.1-54.2%, but data 176 
encompassing a similar combination of items has not been explored previously to our 177 
knowledge. Yet, a limitation of our study is that it included only patients who experience at least 178 
some form of pain, and, thus, our findings cannot be generalized. 179 
On the other hand, it is very well known that pain can interfere with sleep. Specifically, it has 180 
been demonstrated that pain in PD is linked to poorer sleep quality (24,43). In fact, after 181 
removing the PDSS-2 pain-related items, those who reported the presence of any type of pain 182 
on the KPPS had significantly higher scores on the PDSS-2. Moreover, the PDSS-2 score was 183 
moderately or highly correlated with KPPS total score and several domains (i.e. fluctuation-184 
related, nocturnal, discoloration and oedema/swelling, and radicular pain), the VAS-Pain, and 185 
the KPPQ. As these coefficient values were only slightly modified when adjusting for age, PD 186 




duration, motor examination, and LEDD, our results suggest that these PD-related variables do 187 
not associate significantly with the impact of pain on nocturnal sleep. Similarly, Beiske et al. 188 
found that pain was not associated with age, disease duration, or disease severity (2). 189 
Multiple linear regression analyses showed that, among the variables that have been analyzed, 190 
the KPPS and KPPQ were the most relevant predictors of the PDSS-2 total score in their 191 
respective models, while the predictive effect of the VAS-Pain was barely significant in its 192 
model; thus, it can be concluded that pain may have a greater impact on PD patients’ sleep than 193 
other factors and that the PD-specific instruments for pain (i.e. KPPS and KPPQ) may perform 194 
better than generic pain tools (i.e. VAS-Pain). However, a limitation of this analysis is the 195 
presence of a pain-related domain (“PDSS-2 Pain”) in the PDSS-2, which intensified the 196 
relationship between these instruments in such a way that urinary disorders replaced the PD-197 
specific pain evaluations when the PDSS-2 Pain domain was kept out. 198 
Pain and sleep in PD can be pathophysiologically linked. Noradrenergic cells of the locus 199 
coeruleus are known to modulate the cortical signal-to-noise ratio. They are also part of the 200 
medial pain system, which regulates the pain-control system that inhibits the relay nuclei for 201 
somatosensory and viscerosensory inputs (44). In Braak stage 2, stage 1-related PD pathology 202 
becomes more advanced and lesions (mainly Lewy neurites) occur in the medulla oblongata 203 
and pontine tegmentum, including the lower raphe nuclei, the magnocellular portions of the 204 
reticular formation, and the gigantocellular reticular nucleus (45). The coeruleus and raphe 205 
neurons exert an inhibitory effect on the tegmental pedunculopontine nucleus, which stimulates 206 
REM sleep. The reticular cholinergic neurons also regulate arousal mechanisms. As such, the 207 
origins of both pain and sleep dysfunction in PD, even at the premotor Braak stage 2, appear to 208 
be closely related pathophysiologically (46).  209 




Furthermore, when considering only “PDSS-2 Pain,” it showed moderate or high correlations 210 
with several KPPS domains (i.e. musculoskeletal, fluctuation-related, nocturnal, and radicular 211 
pain) and with the KPPS, KPPQ, and VAS-Pain total scores.  212 
Also, another multiple linear regression analysis showed that musculoskeletal and nocturnal 213 
pain were significant predictors of PDSS-2 total score using a model that included only the 214 
domains of the KPPS. These results suggest that specific types of pain are more relevant to 215 
nocturnal sleep problems (44,46). 216 
However, this is not to say that pain is the only predictor of sleep problems in PD. Several 217 
studies have shown that anxiety and depression are also related to poor sleep quality (7,24,47). 218 
In the multiple linear regression model involving the VAS-Pain, the HADS-Depression, followed 219 
by the HADS-Anxiety, was the most p rtinent predictor of PDSS-2 total score. These two 220 
psychiatric measures were also moderately or highly correlated with the PDSS-2.  221 
Neurotransmitter-dysfunction-based non-motor endophenotypes of PD have been recently 222 
proposed, and pain and sleep dysfunction characterize some of these phenotype clusters, 223 
which form part of the limbic- and brainstem-generated cholinergic and serotonergic subtypes of 224 
PD (48,49).  225 
Additionally, the NMSS urinary and gastrointestinal domains as well as the SCOPA-Motor 226 
complications section were also significant predictors of PDSS-2 total score in the models 227 
explored in this study. Similarly, the NMSS domains of sleep/fatigue, mood/apathy, 228 
gastrointestinal, and urinary as well as NMSS total score were also moderately or highly 229 
associated with the PDSS-2. Fatigue, cognitive impairment, and urinary issues were also found 230 
to be significantly associated with sleep quality in another study (7).  231 
Moderate associations were found between the PDSS-2 and the SCOPA-Motor ADL, 232 
complications section, and its total score, as well as between the PDSS-2 and the CISI-PD, 233 




suggesting that motor problems and disability may have some effect on sleep-related issues in 234 
PD (8,50). In fact, nocturnal hypokinesia has recently been highlighted as an important factor 235 
impairing sleep quality (51). 236 
Although PD duration and LEDD were not significant predictors of PDSS-2 total scores, patient 237 
groups with longer PD duration and higher LEDD scored significantly higher on the PDSS-2 238 
than those with shorter PD duration and lower LEDD, suggesting that problems with sleep could 239 
worsen with disease progression (52). Additionally, there were no significant differences 240 
between groups of age and sex in reference to PDSS-2 total score, although differences related 241 
to sex were found in another study (53).  242 
Sleep disturbances and pain are significant factors in patients’ lives as demonstrated by the 243 
moderate-to-high correlations of the PDSS-2, KPPS, KPPQ, and VAS-Pain with both the EQ-244 
5D-3L and the PDQ-8, the two measures of QoL utilized in this study. When considering only 245 
“PDSS-2 Pain,” there were moderate correlations with the EQ-5D-3L’s pain/discomfort question 246 
and PDQ-8 item 8, findings in line with previous studies that identified pain is a determinant 247 
factor of QoL (54).  248 
In conclusion, our results show that (1) nocturnal sleep disorders could affect the majority of PD 249 
patients; (2) pain, as a whole, showed a moderate association with the severity of nocturnal 250 
sleep disorders; and (3) nocturnal sleep disorders could be influenced more by certain subtypes 251 
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Table 1 – Descriptive characteristics of the sample 
 
 Mean SD Maximum Minimum 
Age  64.86 10.54 29 88 
Age at PD onset 59.49 11.15 29 83 
PD duration 5.23 4.83 0 22 
Years of education 14.11 3.99 0 24 
LEDD 587.81 464.15 0 2620 
Scales for Outcomes in PD-Motor  
                Examination 
                Activities of daily living 






















Non-Motor Symptoms Scale 
      Cardiovascular 
      Sleep/Fatigue 
      Mood/Apathy 
      Perceptual problems/Hallucinations 
      Attention/Memory 
      Gastrointestinal tract 
      Urinary 
      Sexual function 
      Miscellaneous 













































Clinical Impression of Severity Index-PD 
          Motor impairment 
          Disability 
          Motor complications 


























Hospital Anxiety and Depression Scale 
          Anxiety 













EQ-5D Index 0.57 0.27 -0.15 1 
PDQ-8 Index 28.67 20.25 0 93.75 
 
PD: Parkinson’s disease. LEDD: Levodopa-equivalent daily dose.  
EQ-5D: EuroQoL questionnaire- 5 dimensions. 
PDQ-8: Parkinson’s disease questionnaire- 8 items. 
SD: Standard deviation. 
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Table 2: Prevalence of Sleep Problems as Assessed by the PDSS-2 
 
Item Prevalence 
1 Bad sleep quality 71.7% 
2 Difficulties falling asleep 45.0% 
3 Difficulties staying asleep 66.0% 
4 Restlessness of legs or arms at nights 53.3% 
5 Urge to move your legs or arms 46.2% 
6 Distressing dreams at night 41.3% 
7 Distressing hallucinations at night 15.3% 
8 Get up at night to pass urine 85.0% 
9 Uncomfortable and immobility at night 54.7% 
10 Pain in arms or legs 50.2% 
11 Muscle cramps in your arms or legs 54.2% 
12 Painful posturing in the morning 44.1% 
13 Tremor on waking 48.2% 
14 Tired and sleepy after waking in the morning 72.0% 
15 Snoring or difficulties in breathing 25.0% 
Total  99.3% 
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Table 3 – Differences in PDSS-2 non-pain-related score based on KPPS pain modality prevalence 
 
KPPS Pain Domain Prevalence PDSS-2 Non-Pain-Related Score Significance (p)* 
Musculoskeletal Pain Absent 11.80±7.33 0.0024 
Present 15.95±8.80 
Chronic Pain Absent 13.31±7.71 <0.0001 
Present 18.97±9.32 
Fluctuation-Related Pain Absent 13.05±7.99 <0.0001 
Present 17.91±8.80 
Nocturnal Pain Absent 11.51±7.70 <0.0001 
Present 18.00±8.35 
Oro-Facial Pain Absent 14.49±8.43 0.0010 
Present 19.64±9.13 
Discoloration & Oedema/Swelling Absent 13.59±8.00 <0.0001 
Present 18.76±9.14 
Radicular Pain Absent 13.24±7.98 <0.0001 
Present 17.88±8.93 
 
KPPS: King’s Parkinson’s Disease Pain Scale  
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2  
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Table 4 – Multiple linear regression models of the PDSS-2 using pain measures 
 
Multiple Linear Regression Model with the KPPS 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
HADS-Anxiety 0.48 0.14 3.44 0.001 0.19 0.41 0.12 3.51 0.001 0.21 
HADS-Depression  0.74 0.17 4.47 <0.001 0.26 0.53 0.14 3.84 <0.001 0.23 
NMSS Urinary Domain 0.21 0.06 3.81 <0.001 0.17 0.22 0.05 4.63 <0.001 0.22 
KPPS 0.16 0.03 5.25 <0.001 0.29 0.08 0.03 2.98 0.003 0.17 
Constant 2.87 3.23 0.89 0.375  5.24 0.83 6.30 <0.001  
F=41.52, p<0.0001; Adj. R-squared=0.49 F=33.90, p<0.0001; Adj. R-squared=0.44 
Multiple Linear Regression Model with the KPPQ 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
HADS-Anxiety 0.47 0.14 3.40 0.001 0.19 0.39 0.12 3.39 0.001 0.20 
HADS-Depression  0.72 0.16 4.39 <0.001 0.25 0.52 0.14 3.79 <0.001 0.23 
NMSS Urinary Domain 0.21 0.06 3.79 <0.001 0.17 0.21 0.05 4.59 <0.001 0.22 
KPPQ 1.24 0.22 5.53 <0.001 0.29 0.72 0.19 3.87 <0.001 0.21 
Constant 4.27 1.04 4.10 <0.001  4.40 0.87 5.08 <0.001  
F=42.29, p<0.0001; Adj. R-squared=0.49 F=35.43, p<0.0001; Adj. R-squared=0.45 
Multiple Linear Regression Model with the VAS-Pain 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
SCOPA-Motor Complic. 0.60 0.21 2.88 0.004 0.14 0.50 0.17 2.98 0.003 0.15 
HADS-Anxiety 0.56 0.14 3.90 <0.001 0.23 0.47 0.12 3.96 <0.001 0.24 
HADS-Depression  0.74 0.17 4.29 <0.001 0.26 0.54 0.14 3.86 <0.001 0.24 
NMSS Gastrointestinal 0.21 0.08 2.44 0.015 0.12 0.15 0.07 2.18 0.030 0.11 
NMSS Urinary Domain 0.24 0.06 4.07 <0.001 0.19 0.23 0.05 4.84 <0.001 0.23 
VAS-Pain 0.04 0.02 2.03 0.043 0.10      
Constant 5.50 1.07 5.13 <0.001  5.41 0.88 6.18 <0.001  
F=35.40, p<0.0001; Adj. R-squared=0.45 F=31.67, p<0.0001; Adj. R-squared=0.42 
 
 
HADS-Anxiety: Hospital Anxiety and Depression Scale – Anxiety 
HADS-Depression: Hospital Anxiety and Depression Scale – Depression 
KPPS: King’s Parkinson’s Disease Pain Scale  
NMSS: Non-Motor Symptoms Scale 
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2 
SCOPA-Motor: Scales for Outcomes in Parkinson’s Disease – Motor  
VAS-Pain: Visual Analog Scale – Pain  
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Table 5 – KPPS pain modalities as predictors of the PDSS-2 using a multiple linear regression model  
 
Multiple Linear Regression Model Using the KPPS Pain Modalities 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
PDSS-2 Total Score Coef SE t p Beta Coef SE t p Beta 
Musculoskeletal Pain 0.41 0.14 2.99 0.003 0.15 0.28 0.12 2.44 0.015 0.13 
Chronic Pain 0.18 0.12 1.55 0.122 0.09 0.13 0.10 1.33 0.184 0.08 
Fluctuation-related Pain 0.14 0.08 1.86 0.064 0.10 0.12 0.67 1.80 0.073 0.11 
Nocturnal Pain 0.71 0.11 6.40 <0.001 0.35 0.47 0.09 4.96 <0.001 0.29 
Oro-facial Pain 0.21 0.26 0.79 0.427 0.04 0.18 0.22 0.80 0.422 0.04 
Discoloration, Oedema/SP 0.23 0.15 1.52 0.128 0.08 0.15 0.13 1.20 0.232 0.07 
Radicular Pain 0.32 0.17 1.93 0.054 0.10 0.19 0.14 1.26 0.210 0.07 
                  Constant 10.50 0.97 10.82 <0.001  9.65 0.83 11.67 <0.001  
F=22.13, p<0.0001; Adj. R-squared=0.33 F=14.13, p<0.0001; Adj. R squared=0.24 
 
KPPS: King’s Parkinson’s Disease Pain Scale  
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2 
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Background: Little research has been conducted regarding the relationship between sleep 
disorders and different pain types in Parkinson’s disease (PD). 
Objective: To explore the influence of the various pain subtypes experienced by PD patients on 
sleep. 
Methods: Three-hundred consecutive PD patients were assessed with the PD Sleep Scale-
Version 2 (PDSS-2), King’s PD Pain Scale (KPPS), King’s PD Pain Questionnaire (KPPQ), 
Visual Analog Scales for Pain (VAS-Pain), and Hospital Anxiety and Depression Scale. 
Results: According to the PDSS-2, 99.3% of our sample suffered from at least one sleep issue. 
Those who reported experiencing any modality of pain suffered significantly more from sleep 
disorders than those who did not (all, p<0.003). The PDSS-2 showed moderate-to-high 
correlations with the KPPS (rS=0.57), KPPQ (0.57), and VAS-Pain (0.35). When PDSS-2 items 
10-12 (pain-related) were excluded, the correlation values decreased to 0.50., 0.51, and 0.28, 
respectively, while these items showed moderate-to-high correlations with KPPS (0.56), KPPQ 
(0.54), and VAS-Pain (0.42). Among the variables analyzed, multiple linear regression models 
suggested that KPPS and KPPQ were the most relevant predictors of sleep disorders (as per 
the PDSS-2), although following exclusion of PDSS-2 pain items depression was the relevant 
predictor. Depression and anxiety were the most relevant predictors in the analysis involving the 
VAS-Pain. Regression analysis considering only the KPPS domains showed that nocturnal and 
musculoskeletal pain were the best predictors of overall nocturnal sleep disorder. 
Conclusions: Pain showed a moderate association with nocturnal sleep dysfunction in PD. 
Some pain subtypes had a greater effect on sleep than others. 
 






A range of sleep disorders and subtypes of pain, are very prevalent non-motor symptoms of 3 
Parkinson’s disease (PD) that occur from the prodromal to the palliative stages of PD (1-5). 4 
Sleep dysfunction, which affects 60-98% of PD patients, may be manifested as insomnia, sleep 5 
disruption, sudden onset of sleep, rapid-eye-movement (REM) sleep behavior disorder, non-6 
REM parasomnias, and restless legs syndrome (6-8). Surveys suggest that insomnia affects 7 
46% of PD patients, vivid dreams 34%, acting out while dreaming 36%, and restless legs 8 
syndrome 42% (1). Depression, anxiety, cognitive problems, stress, and daytime sleepiness 9 
have been found to result from these conditions, and sleep disorders in PD have a negative 10 
impact on patients’ quality of life (QoL) (9,10).  11 
On the other hand, using the King’s Parkinson’s Disease Pain Scale (KPPS) (11), the syndromic 12 
nature of pain has been formally subdivided into several patterns. Prior research has shown that 13 
the prevalence of pain is 68-81% in PD patients (12-14) and that it can be manifested in several 14 
modalities, such as musculoskeletal (41-89%), dystonic (15-17%), radicular-neuropathic (27-15 
32%), and central pain (4-22%) (2,12,14-18). Furthermore, 35% of PD patients are affected by 16 
two types of pain, 10% by three, and 2% by four (14). Pain can become crippling in a subset of 17 
PD patients, affect their ability to conduct activities of daily living (ADL) (13,19), and negatively 18 
impact their QoL (20-22). Yet, despite the impact of this non-motor symptom, pain often remains 19 
underdiagnosed and undeclared (23).  20 
PD patients with pain have been found to experience poorer sleep quality and more sleep 21 
disorders than patients without pain (24). Using the Parkinson’s Disease Sleep Scale-Version 2 22 
(PDSS-2) (25) and the KPPS (11), the present study seeks both to explore the influence of the 23 
various modalities of pain experienced by PD patients on sleep disorders and to examine the 24 




relationship between sleep disorders and other factors, such as anxiety and depression, motor 25 




International, multicenter, observational, cross-sectional study. 30 
Patients 31 
Consecutive PD patients were included in this study if they were diagnosed with PD according 32 
to the UK PD Brain Bank criteria (26) and if they declared unexplained pains on item 10 of the 33 
Non-Motor Symptoms Questionnaire (27). However, if patients had an alternative or uncertain 34 
diagnosis of PD or drug-induced PD, were unable to consent, had dementia as diagnosed by 35 
international criteria, or were diagnosed with known conditions that cause pain unrelated to PD 36 
(e.g. arthritis, malignancy, etc.), they were excluded from this study (28). 37 
Patients were recruited from nine different movement disorder centers across the United 38 
Kingdom (eight) and Romania (one) from August 2013 to February 2016. This study was 39 
conducted under the UK’s National Institute of Health Research’s portfolio of studies (UKCRN 40 
No. 13344) (28). 41 
Ethical issues 42 
The study was approved by the respective hospital ethical committees/institutional review 43 
boards. All participants provided informed consent before inclusion in the study. 44 
Assessments 45 




Socio-demographic data and disease history (i.e. sex, age, ethnicity, PD duration, current 46 
treatment, and surgery) were collected from all patients. According to Tomlinson et al., levodopa 47 
equivalent daily dose (LEDD) was also calculated (29). 48 
The following instruments were used to assess each patient: 49 
1. Parkinson’s Disease Sleep Scale-Version 2 (PDSS-2) (25), a 15-item, patient-completed 50 
clinical tool used to assess the frequency of sleep disturbances during the past week in PD 51 
patients. Items 10, 11, and 12 of the PDSS-2 directly assess pain while sleeping or when 52 
waking up. 53 
2. Hoehn-Yahr classification (HY) (30), a five-stage system that classifies PD on a 54 
continuum from unilateral expression of the disease to the most severe. 55 
3. Scales for Outcomes in Parkinson’s Disease-Motor (SCOPA-Motor) (31), a 21-item 56 
scale that measures motor impairment, difficulty with ADL, and motor complications. 57 
4. Non-Motor Symptoms Scale (NMSS) (32), a 30-item scale that considers the frequency 58 
and severity of the non-motor symptoms of PD grouped into nine domains: cardiovascular, 59 
sleep/fatigue, mood/apathy, perceptual problems/hallucinations, attention/memory, 60 
gastrointestinal tract, urinary function, sexual function, and miscellaneous. Item 27 of the NMSS 61 
directly inquires about unexplained pains. 62 
5. Clinical Impression of Severity Index for PD (CISI-PD) (33), an overall estimate of PD 63 
based on motor signs, disability, motor complications, and cognitive status. 64 
6. King’s Parkinson’s Pain Scale (KPPS) (11), a 14-item scale that evaluates the types of 65 
pain suffered by PD patients: musculoskeletal, chronic, fluctuation-related, nocturnal, oro-facial, 66 
discoloration and oedema/swelling, and radicular pain. Each item is rated by the clinician 67 
according to its severity (from 0 to 3) and frequency (from 0 to 4). An item’s score is then 68 




calculated as the product of each pain type’s frequency and severity, and a total score is 69 
calculated by summing the scores of each item. KPPS time frame is “the past month”. 70 
7.   King’s Parkinson’s Pain Questionnaire (KPPQ) (28), a patient-completed derivative of 71 
the KPPS, asks about the same pain modalities as the KPPS, and only provides information 72 
regarding the presence or absence of 14 specific types of pain in a given patient. The time 73 
framework is “past month”.   74 
8. Visual Analog Scales for Pain Severity and Frequency (VAS-Pain) (34). A VAS-Pain 75 
total score was calculated by multiplying both scales, whose time framework was “past month”.  76 
9 Hospital Anxiety and Depression Scale (HADS) (35), which is a 14-item, patient-77 
completed scale with subscales for anxiety and depression. 78 
10. EQ-5D-3L (36), which contains five items that inquire about mobility, self-care, usual 79 
activities, pain/discomfort, and anxiety/depression, as well as a visual analog scale that 80 
assesses current health status. 81 
11. Parkinson’s Disease Questionnaire-8 items (PDQ-8) (37), a PD-specific health-related 82 
QoL measure. Item 8 of the PDQ-8 specifically asks about painful muscle cramps or spasms. 83 
 84 
Data Analysis 85 
Data were anonymized and sent to the National Center of Epidemiology, Carlos III Institute of 86 
Health, in Madrid, Spain for analysis. 87 
Socio-demographic, historical data, and rating scales scores were examined using descriptive 88 
statistics (i.e. mean, median, and, standard deviation). Main data showed non-normal 89 
distribution (Shapiro-Francia test); therefore non-parametric statistical tests were used. 90 




The prevalence of each sleep symptom assessed by the PDSS-2 was calculated by considering 91 
an item score ≥1 to be the presence of that symptom and an item score of 0 to be its absence. 92 
Furthermore, patients were divided into groups using the prevalence of each of the seven pain 93 
modalities (domains) assessed by the KPPS, which were calculated using the same method 94 
described above (15). Then, after excluding the PDSS-2 pain-related items (items 10-12: 95 
“PDSS-2 Pain”), the effect of each type of pain on non-pain-related PDSS-2 score was 96 
determined by comparing the means of the two groups (with and without that specific pain) and 97 
by applying the Mann-Whitney test.  98 
The association of the PDSS-2 with the KPPS and other clinical variables evaluating pain 99 
present in the study was assessed by Spearman correlations. Partial correlations were also 100 
used to adjust these associations for age, PD duration, SCOPA motor examination, and LEDD. 101 
Coefficient values higher than 0.50 were deemed strong correlations and those from 0.30 to 102 
0.49 moderate ones.  103 
The influence of pain on PDSS-2 score was determined using multiple linear regression models 104 
in which the dependent variable was the PDSS-2 and the independent ones were (after 105 
checking for association, collinearity, and interaction): SCOPA-Motor ADL and complications 106 
sections, HADS-Anxiety, HADS-Depression, and the NMSS gastrointestinal and urinary 107 
domains. Each model also included one of the following pain measures as an independent 108 
variable: KPPS, KPPQ, and VAS-Pain. In order to explore the influence of each type of pain on 109 
nocturnal sleep issues, another multiple linear regression analysis was conducted using the 110 
KPPS domains as predictors of PDSS-2 total score.  111 
To exclude the influence of the PDSS-2 pain-related items on the findings, the correlation 112 
coefficients and multiple regression models were recalculated after excluding the “PDSS-2 Pain” 113 
dimension. 114 




For further analysis regarding the PDSS-2 total score, Kruskal-Wallis and Mann-Whitney tests 115 
were conducted to determine if there were significant differences between sexes, groups of age, 116 
PD duration, and LEDD (based on quartiles) in reference to the scale. Finally, Spearman rank 117 
correlations were calculated between PDSS-2 and the remaining assessments in the study.  118 
 119 
Results 120 
Three hundred PD patients, most of them males (59.7%) and predominantly Caucasians 121 
(84.8%) were included in the study. Median HY was 2 with an interquartile range of 2–3 (limits: 122 
1–5). One hundred and fifty one patients (50.3%) had Postural instability and gait difficulty PD 123 
subtype; 93 (31.0%) showed tremor predominant subtype; and 56 (18.7%) were indeterminate 124 
(38,39). Other descriptive data of the sample are displayed in the Table 1. On the PDSS-2, the 125 
average total score was 18.57±10.89 (range: 0–51), while scores were 22.85±19.45 (0–102) on 126 
the KPPS, 3.96±2.56 (1–12) on the KPPQ, and 32.78±24.40 (0–100) on the VAS-Pain.  127 
Table 2 shows the prevalence rates for each sleep issue assessed by the PDSS-2; 99.3% of 128 
our sample was afflicted by at least one sleep problem. Moreover, as shown in Table 3, those 129 
who reported experiencing any modality of pain suffered from significantly more severe non-130 
pain-related sleep disorders than those who did not (all, p<0.003).  131 
The PDSS-2 was moderately or highly correlated with the KPPS domains of fluctuation-related 132 
pain (rS=0.34), nocturnal pain (0.52), discoloration and oedema/swelling related pain (0.31), and 133 
radicular pain (0.32) as well as with the KPPS total score (0.57), whereas it showed weak 134 
relationships with the remaining KPPS domains (rS=0.20–0.28). Similarly, the correlations with 135 
KPPQ (0.57) and VAS-Pain (0.35) were moderate-to-high. These coefficients were only slightly 136 
modified in the partial correlation analysis of total scores (KPPS, 0.51; KPPQ, 0.52; and VAS-137 
Pain, 0.31). When the “PDSS-2 Pain” component was excluded from the PDSS-2 total score, all 138 




correlation coefficients with total scores decreased 0.06-0.07 (KPPS, 0.50; KPPQ, 0.51, VAS-139 
Pain, 0.28), and 0.04 in average (0.01-0.08) with KPPS domains. Furthermore, the two QoL 140 
assessments showed moderate-to-high associations with the three pain measures in the study: 141 
-0.45 to -0.60 for the EQ-5D-3L and 0.42 to 0.59 for the PDQ-8. 142 
Using “PDSS-2 Pain” (the sum of items 10-12), the following correlations were found between 143 
this pain score and other measures in the study: the KPPS domains of musculoskeletal 144 
(rS=0.30), fluctuation-related (0.32), nocturnal (0.52), and radicular (0.37) pain as well as its total 145 
score (0.56); the KPPQ (0.54); VAS-Pain (0.42); the EQ-5D-3L’s pain/discomfort question 146 
(0.37); and PDQ-8 item 8 (0.43).  147 
Table 4 shows the results of six multiple linear regression models. In the analyses using the 148 
KPPS and KPPQ, pain was shown to be the most powerful predictor of the sleep disorders 149 
assessed by the PDSS-2 (p<0.001); however, in the analysis using the VAS-Pain, depression 150 
and then anxiety were the best predictors of these sleep problems (p<0.001). However, when 151 
the “PDSS-2 Pain” domain was excluded, depression and urinary disorders were first and 152 
second determinants in importance in the models with KPPS and KPPQ, whereas there were no 153 
changes in those of the VAS-Pain model (Table 4). 154 
An additional multiple linear regression model using the KPPS pain modalities as predictors of 155 
the PDSS-2 was explored. In this model, only nocturnal (p<0.001; beta=0.38) and 156 
musculoskeletal (p=0.003; beta=0.15) pain were significant determinants of overall nocturnal 157 
sleep disorder, a finding that was not modified by excluding the pain-related items of the PDSS-158 
2 (Table 5).  159 
Patients who had longer PD duration (p=0.001) and higher LEDD (p<0.001) also reported 160 
significantly more severe sleep disturbances. Moreover, the PDSS-2 showed moderate-to-high 161 
correlations with the other clinical measures in the study: CISI total score (rS=0.39); HADS-162 




Anxiety (0.50); HADS-Depression (0.54); EQ-5D summary index (-0.49); PDQ-8 summary index 163 
(0.60); SCOPA-Motor ADL (0.43), complications (0.38), and total score (0.40); the NMSS 164 
domains of sleep/fatigue (0.58), mood/apathy (0.34), gastrointestinal (0.37), urinary (0.35), and 165 
its total score (0.54).  166 
 167 
Discussion 168 
In line with previous findings, almost all patients in our sample (99.3%) declared having at least 169 
one nocturnal sleep dysfunction according to the PDSS-2, confirming the high prevalence of this 170 
non-motor symptom in PD (6). The most prevalent of these issues in our study were nocturia 171 
(85.0%), tiredness and sleepiness upon waking (72.0%), and poor sleep quality (71.7%). While 172 
some studies have found figures that are similar to ours, other studies did not (40-42); however, 173 
the PDSS-2 has never been used to analyze the prevalence of nocturnal sleep disorders in PD, 174 
and, therefore, our results cannot be compared at present with other studies. For example, 175 
problems related to “PDSS-2 Pain” showed prevalence rates of 44.1-54.2%, but data 176 
encompassing a similar combination of items has not been explored previously to our 177 
knowledge. Yet, a limitation of our study is that it included only patients who experience at least 178 
some form of pain, and, thus, our findings cannot be generalized. 179 
On the other hand, it is very well known that pain can interfere with sleep. Specifically, it has 180 
been demonstrated that pain in PD is linked to poorer sleep quality (24,43). In fact, after 181 
removing the PDSS-2 pain-related items, those who reported the presence of any type of pain 182 
on the KPPS had significantly higher scores on the PDSS-2. Moreover, the PDSS-2 score was 183 
moderately or highly correlated with KPPS total score and several domains (i.e. fluctuation-184 
related, nocturnal, discoloration and oedema/swelling, and radicular pain), the VAS-Pain, and 185 
the KPPQ. As these coefficient values were only slightly modified when adjusting for age, PD 186 




duration, motor examination, and LEDD, our results suggest that these PD-related variables do 187 
not associate significantly with the impact of pain on nocturnal sleep. Similarly, Beiske et al. 188 
found that pain was not associated with age, disease duration, or disease severity (2). 189 
Multiple linear regression analyses showed that, among the variables that have been analyzed, 190 
the KPPS and KPPQ were the most relevant predictors of the PDSS-2 total score in their 191 
respective models, while the predictive effect of the VAS-Pain was barely significant in its 192 
model; thus, it can be concluded that pain may have a greater impact on PD patients’ sleep than 193 
other factors and that the PD-specific instruments for pain (i.e. KPPS and KPPQ) may perform 194 
better than generic pain tools (i.e. VAS-Pain). However, a limitation of this analysis is the 195 
presence of a pain-related domain (“PDSS-2 Pain”) in the PDSS-2, which intensified the 196 
relationship between these instruments in such a way that urinary disorders replaced the PD-197 
specific pain evaluations when the PDSS-2 Pain domain was kept out. 198 
Pain and sleep in PD can be pathophysiologically linked. Noradrenergic cells of the locus 199 
coeruleus are known to modulate the cortical signal-to-noise ratio. They are also part of the 200 
medial pain system, which regulates the pain-control system that inhibits the relay nuclei for 201 
somatosensory and viscerosensory inputs (44). In Braak stage 2, stage 1-related PD pathology 202 
becomes more advanced and lesions (mainly Lewy neurites) occur in the medulla oblongata 203 
and pontine tegmentum, including the lower raphe nuclei, the magnocellular portions of the 204 
reticular formation, and the gigantocellular reticular nucleus (45). The coeruleus and raphe 205 
neurons exert an inhibitory effect on the tegmental pedunculopontine nucleus, which stimulates 206 
REM sleep. The reticular cholinergic neurons also regulate arousal mechanisms. As such, the 207 
origins of both pain and sleep dysfunction in PD, even at the premotor Braak stage 2, appear to 208 
be closely related pathophysiologically (46).  209 




Furthermore, when considering only “PDSS-2 Pain,” it showed moderate or high correlations 210 
with several KPPS domains (i.e. musculoskeletal, fluctuation-related, nocturnal, and radicular 211 
pain) and with the KPPS, KPPQ, and VAS-Pain total scores.  212 
Also, another multiple linear regression analysis showed that musculoskeletal and nocturnal 213 
pain were significant predictors of PDSS-2 total score using a model that included only the 214 
domains of the KPPS. These results suggest that specific types of pain are more relevant to 215 
nocturnal sleep problems (44,46). 216 
However, this is not to say that pain is the only predictor of sleep problems in PD. Several 217 
studies have shown that anxiety and depression are also related to poor sleep quality (7,24,47). 218 
In the multiple linear regression model involving the VAS-Pain, the HADS-Depression, followed 219 
by the HADS-Anxiety, was the most p rtinent predictor of PDSS-2 total score. These two 220 
psychiatric measures were also moderately or highly correlated with the PDSS-2.  221 
Neurotransmitter-dysfunction-based non-motor endophenotypes of PD have been recently 222 
proposed, and pain and sleep dysfunction characterize some of these phenotype clusters, 223 
which form part of the limbic- and brainstem-generated cholinergic and serotonergic subtypes of 224 
PD (48,49).  225 
Additionally, the NMSS urinary and gastrointestinal domains as well as the SCOPA-Motor 226 
complications section were also significant predictors of PDSS-2 total score in the models 227 
explored in this study. Similarly, the NMSS domains of sleep/fatigue, mood/apathy, 228 
gastrointestinal, and urinary as well as NMSS total score were also moderately or highly 229 
associated with the PDSS-2. Fatigue, cognitive impairment, and urinary issues were also found 230 
to be significantly associated with sleep quality in another study (7).  231 
Moderate associations were found between the PDSS-2 and the SCOPA-Motor ADL, 232 
complications section, and its total score, as well as between the PDSS-2 and the CISI-PD, 233 




suggesting that motor problems and disability may have some effect on sleep-related issues in 234 
PD (8,50). In fact, nocturnal hypokinesia has recently been highlighted as an important factor 235 
impairing sleep quality (51). 236 
Although PD duration and LEDD were not significant predictors of PDSS-2 total scores, patient 237 
groups with longer PD duration and higher LEDD scored significantly higher on the PDSS-2 238 
than those with shorter PD duration and lower LEDD, suggesting that problems with sleep could 239 
worsen with disease progression (52). Additionally, there were no significant differences 240 
between groups of age and sex in reference to PDSS-2 total score, although differences related 241 
to sex were found in another study (53).  242 
Sleep disturbances and pain are significant factors in patients’ lives as demonstrated by the 243 
moderate-to-high correlations of the PDSS-2, KPPS, KPPQ, and VAS-Pain with both the EQ-244 
5D-3L and the PDQ-8, the two measures of QoL utilized in this study. When considering only 245 
“PDSS-2 Pain,” there were moderate correlations with the EQ-5D-3L’s pain/discomfort question 246 
and PDQ-8 item 8, findings in line with previous studies that identified pain is a determinant 247 
factor of QoL (54).  248 
In conclusion, our results show that (1) nocturnal sleep disorders could affect the majority of PD 249 
patients; (2) pain, as a whole, showed a moderate association with the severity of nocturnal 250 
sleep disorders; and (3) nocturnal sleep disorders could be influenced more by certain subtypes 251 
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Table 1 – Descriptive characteristics of the sample 
 
 Mean SD Maximum Minimum 
Age  64.86 10.54 29 88 
Age at PD onset 59.49 11.15 29 83 
PD duration 5.23 4.83 0 22 
Years of education 14.11 3.99 0 24 
LEDD 587.81 464.15 0 2620 
Scales for Outcomes in PD-Motor  
                Examination 
                Activities of daily living 






















Non-Motor Symptoms Scale 
      Cardiovascular 
      Sleep/Fatigue 
      Mood/Apathy 
      Perceptual problems/Hallucinations 
      Attention/Memory 
      Gastrointestinal tract 
      Urinary 
      Sexual function 
      Miscellaneous 













































Clinical Impression of Severity Index-PD 
          Motor impairment 
          Disability 
          Motor complications 


























Hospital Anxiety and Depression Scale 
          Anxiety 













EQ-5D Index 0.57 0.27 -0.15 1 
PDQ-8 Index 28.67 20.25 0 93.75 
 
PD: Parkinson’s disease. LEDD: Levodopa-equivalent daily dose.  
EQ-5D: EuroQoL questionnaire- 5 dimensions. 
PDQ-8: Parkinson’s disease questionnaire- 8 items. 
SD: Standard deviation. 
 




Table 2: Prevalence of Sleep Problems as Assessed by the PDSS-2 
 
Item Prevalence 
1 Bad sleep quality 71.7% 
2 Difficulties falling asleep 45.0% 
3 Difficulties staying asleep 66.0% 
4 Restlessness of legs or arms at nights 53.3% 
5 Urge to move your legs or arms 46.2% 
6 Distressing dreams at night 41.3% 
7 Distressing hallucinations at night 15.3% 
8 Get up at night to pass urine 85.0% 
9 Uncomfortable and immobility at night 54.7% 
10 Pain in arms or legs 50.2% 
11 Muscle cramps in your arms or legs 54.2% 
12 Painful posturing in the morning 44.1% 
13 Tremor on waking 48.2% 
14 Tired and sleepy after waking in the morning 72.0% 
15 Snoring or difficulties in breathing 25.0% 
Total  99.3% 
 

















Table 3 – Differences in PDSS-2 non-pain-related score based on KPPS pain modality prevalence 
 
KPPS Pain Domain Prevalence PDSS-2 Non-Pain-Related Score Significance (p)* 
Musculoskeletal Pain Absent 11.80±7.33 0.0024 
Present 15.95±8.80 
Chronic Pain Absent 13.31±7.71 <0.0001 
Present 18.97±9.32 
Fluctuation-Related Pain Absent 13.05±7.99 <0.0001 
Present 17.91±8.80 
Nocturnal Pain Absent 11.51±7.70 <0.0001 
Present 18.00±8.35 
Oro-Facial Pain Absent 14.49±8.43 0.0010 
Present 19.64±9.13 
Discoloration & Oedema/Swelling Absent 13.59±8.00 <0.0001 
Present 18.76±9.14 
Radicular Pain Absent 13.24±7.98 <0.0001 
Present 17.88±8.93 
 
KPPS: King’s Parkinson’s Disease Pain Scale  
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2  
















Table 4 – Multiple linear regression models of the PDSS-2 using pain measures 
 
Multiple Linear Regression Model with the KPPS 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
HADS-Anxiety 0.48 0.14 3.44 0.001 0.19 0.41 0.12 3.51 0.001 0.21 
HADS-Depression  0.74 0.17 4.47 <0.001 0.26 0.53 0.14 3.84 <0.001 0.23 
NMSS Urinary Domain 0.21 0.06 3.81 <0.001 0.17 0.22 0.05 4.63 <0.001 0.22 
KPPS 0.16 0.03 5.25 <0.001 0.29 0.08 0.03 2.98 0.003 0.17 
Constant 2.87 3.23 0.89 0.375  5.24 0.83 6.30 <0.001  
F=41.52, p<0.0001; Adj. R-squared=0.49 F=33.90, p<0.0001; Adj. R-squared=0.44 
Multiple Linear Regression Model with the KPPQ 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
HADS-Anxiety 0.47 0.14 3.40 0.001 0.19 0.39 0.12 3.39 0.001 0.20 
HADS-Depression  0.72 0.16 4.39 <0.001 0.25 0.52 0.14 3.79 <0.001 0.23 
NMSS Urinary Domain 0.21 0.06 3.79 <0.001 0.17 0.21 0.05 4.59 <0.001 0.22 
KPPQ 1.24 0.22 5.53 <0.001 0.29 0.72 0.19 3.87 <0.001 0.21 
Constant 4.27 1.04 4.10 <0.001  4.40 0.87 5.08 <0.001  
F=42.29, p<0.0001; Adj. R-squared=0.49 F=35.43, p<0.0001; Adj. R-squared=0.45 
Multiple Linear Regression Model with the VAS-Pain 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
 Coeff SE t p Beta Coeff SE t p Beta 
SCOPA-Motor Complic. 0.60 0.21 2.88 0.004 0.14 0.50 0.17 2.98 0.003 0.15 
HADS-Anxiety 0.56 0.14 3.90 <0.001 0.23 0.47 0.12 3.96 <0.001 0.24 
HADS-Depression  0.74 0.17 4.29 <0.001 0.26 0.54 0.14 3.86 <0.001 0.24 
NMSS Gastrointestinal 0.21 0.08 2.44 0.015 0.12 0.15 0.07 2.18 0.030 0.11 
NMSS Urinary Domain 0.24 0.06 4.07 <0.001 0.19 0.23 0.05 4.84 <0.001 0.23 
VAS-Pain 0.04 0.02 2.03 0.043 0.10      
Constant 5.50 1.07 5.13 <0.001  5.41 0.88 6.18 <0.001  
F=35.40, p<0.0001; Adj. R-squared=0.45 F=31.67, p<0.0001; Adj. R-squared=0.42 
 
 
HADS-Anxiety: Hospital Anxiety and Depression Scale – Anxiety 
HADS-Depression: Hospital Anxiety and Depression Scale – Depression 
KPPS: King’s Parkinson’s Disease Pain Scale  
NMSS: Non-Motor Symptoms Scale 
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2 
SCOPA-Motor: Scales for Outcomes in Parkinson’s Disease – Motor  
VAS-Pain: Visual Analog Scale – Pain  





Table 5 – KPPS pain modalities as predictors of the PDSS-2 using a multiple linear regression model  
 
Multiple Linear Regression Model Using the KPPS Pain Modalities 
 
PDSS-2 Total Score 
PDSS-2 Total Score  
without pain domain 
PDSS-2 Total Score Coef SE t p Beta Coef SE t p Beta 
Musculoskeletal Pain 0.41 0.14 2.99 0.003 0.15 0.28 0.12 2.44 0.015 0.13 
Chronic Pain 0.18 0.12 1.55 0.122 0.09 0.13 0.10 1.33 0.184 0.08 
Fluctuation-related Pain 0.14 0.08 1.86 0.064 0.10 0.12 0.67 1.80 0.073 0.11 
Nocturnal Pain 0.71 0.11 6.40 <0.001 0.35 0.47 0.09 4.96 <0.001 0.29 
Oro-facial Pain 0.21 0.26 0.79 0.427 0.04 0.18 0.22 0.80 0.422 0.04 
Discoloration, Oedema/SP 0.23 0.15 1.52 0.128 0.08 0.15 0.13 1.20 0.232 0.07 
Radicular Pain 0.32 0.17 1.93 0.054 0.10 0.19 0.14 1.26 0.210 0.07 
                  Constant 10.50 0.97 10.82 <0.001  9.65 0.83 11.67 <0.001  
F=22.13, p<0.0001; Adj. R-squared=0.33 F=14.13, p<0.0001; Adj. R squared=0.24 
 
KPPS: King’s Parkinson’s Disease Pain Scale  
PDSS-2: Parkinson’s Disease Sleep Scale – Version 2 
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